In:
Biomedicines, MDPI AG, Vol. 9, No. 1 ( 2020-12-22), p. 1-
Abstract:
This review summarizes recent developments regarding molecular imaging markers for magnetic resonance imaging (MRI) of prostate cancer (PCa). Currently, the clinical standard includes MR imaging using unspecific gadolinium-based contrast agents. Specific molecular probes for the diagnosis of PCa could improve the molecular characterization of the tumor in a non-invasive examination. Furthermore, molecular probes could enable targeted therapies to suppress tumor growth or reduce the tumor size.
Type of Medium:
Online Resource
ISSN:
2227-9059
DOI:
10.3390/biomedicines9010001
Language:
English
Publisher:
MDPI AG
Publication Date:
2020
detail.hit.zdb_id:
2720867-9